Litcius/Paper detail

New chalcone derivatives as effective against SARS‐CoV‐2 agent

Nizami Duran, M. Fatih Polat, Derya Aktaş, Mehmet Abdullah Alagöz, Emrah Ay, Funda Çimen, Erhan Tek, Barış Anıl, Serdar Burmaoğlu, Öztekin Algül

2021International Journal of Clinical Practice40 citationsDOIOpen Access PDF

Abstract

AIMS: Flavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs. METHODS: ) values. RESULTS: Antiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS-CoV-2 at the concentration of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti-coronavirus disease-2019 drug candidates. CONCLUSIONS: Computational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from -4.370 to -2.748 kcal/mol along with their toxicological, ADME, and drug-like properties.

Topics & Concepts

MedicineChalconeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyInternal medicineStereochemistryInfectious disease (medical specialty)OutbreakDiseaseChemistryComputational Drug Discovery MethodsCOVID-19 Clinical Research StudiesBioactive natural compounds